Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.

Strowd RE, Blackwood R, Brown M, Harmon M, Lovato J, Yalcinkaya T, Lesser G.

J Oncol Pharm Pract. 2013 Dec;19(4):321-7. doi: 10.1177/1078155212469243. Epub 2013 Jan 4.

2.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

3.

Temozolomide in malignant gliomas: current use and future targets.

Villano JL, Seery TE, Bressler LR.

Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55. doi: 10.1007/s00280-009-1050-5. Epub 2009 Jun 19. Review.

PMID:
19543728
4.

Current and future developments in the use of temozolomide for the treatment of brain tumours.

Stupp R, Gander M, Leyvraz S, Newlands E.

Lancet Oncol. 2001 Sep;2(9):552-60. Review.

PMID:
11905710
5.

Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.

Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J.

Molecules. 2009 Apr 16;14(4):1561-77. doi: 10.3390/molecules14041561. Review.

6.

New approaches for temozolomide therapy: use in newly diagnosed glioma.

Stupp R, Newlands E.

Semin Oncol. 2001 Aug;28(4 Suppl 13):19-23. Review.

PMID:
11550135
7.

Temozolomide and treatment of malignant glioma.

Friedman HS, Kerby T, Calvert H.

Clin Cancer Res. 2000 Jul;6(7):2585-97. Review.

8.

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ.

Lancet Oncol. 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. Review.

PMID:
18452856
9.

Temozolomide: realizing the promise and potential.

Nagasubramanian R, Dolan ME.

Curr Opin Oncol. 2003 Nov;15(6):412-8. Review.

PMID:
14624222
10.
11.

The use of temozolomide in recurrent malignant gliomas.

Gaya A, Rees J, Greenstein A, Stebbing J.

Cancer Treat Rev. 2002 Apr;28(2):115-20. Review.

PMID:
12297119
12.

[Glioma therapy up-date].

de la Fuente BP, Dalmau J, Rosenfeld M.

Neurologia. 2007 Apr;22(3):159-69. Review. Spanish.

PMID:
17364254
13.

Temozolomide: Expanding its role in brain cancer.

Mrugala MM, Adair J, Kiem HP.

Drugs Today (Barc). 2010 Nov;46(11):833-46. doi: 10.1358/dot.2010.46.11.1549024. Review.

PMID:
21225022
14.

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

Singhal N, Selva-Nayagam S, Brown MP.

J Neurooncol. 2007 Nov;85(2):229-30. Epub 2007 May 26. Review.

PMID:
17530175

Supplemental Content

Support Center